About 32 results found for searched term "POT-4" (0.06 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M3173 | Potassium canrenoate | Mineralocorticoid Receptor |
| Aldadiene potassium, SC-14266 | ||
| Canrenoate potassium is a predrug for the release of Canrenone and an effective antagonist of competitive salt ocorticoid receptor. As a diuretic, Canrenoate potassium is used in the study of hypertension. | ||
| M54080 | POT-4 | Complement System |
| POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. | ||
| M1636 | Abiraterone | Cytochrome P450 (e.g. CYP17) |
| CB-7598 | ||
| Abiraterone acetate (CB-7598) is a potent, selective, and orally available inhibitor of CYP17 with an IC50 of 4 nM. | ||
| M1656 | Tivozanib (AV-951) | VEGFR/PDGFR |
| KRN951; Tivozanib | ||
| AV-951 (Tivozanib) is a potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM respectively. | ||
| M1661 | AZD6244 | MEK |
| Selumetinib, ARRY-142886 | ||
| AZD6244 (ARRY-142886, Selumetinib) is a potent MEK 1/2 inhibitor with GI50 values ranging from 14 to 50 nM. | ||
| M1667 | Sapitinib (AZD8931) | EGFR/HER2 |
| AZD-8931 | ||
| AZD8931 (Sapitinib) is an equipotent, reversible inhibitor of Signaling by EGFR, ERBB2 (HER2), and ERBB3 with IC50 of 4, 3, 4 nM respectively. | ||
| M1671 | BEZ235 | PI3K |
| NVP-BEZ235, Dactolisib | ||
| BEZ235 (NVP-BEZ235) is a potent dual PI3K and mTOR inhibitor of p110α, p110γ, p110δ and p110β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM, respectively. | ||
| M1672 | BI 2536 | PLK |
| BI 2536 is a novel, highly selective, potent dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively. | ||
| M1682 | BMS-777607 | c-Met |
| BMS 817378; CAS# 1025720-94-8 | ||
| BMS-777607 is a selective and potent small-molecule met kinase inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively. | ||
| M1693 | CUDC-101 | HDAC |
| Curis | ||
| CUDC-101 is a potent multitargeted HDAC, EGFR and HER2 inhibitor with IC50 of 4.4, 2.4, and 15.7 nM, respectively. | ||
| M1694 | CYC116 | Aurora Kinase |
| CYC116 is a potent, small molecule inhibitor of Aurora A, B and C with IC50 value of 44, 19 and 65 nM respectively. | ||
| M1713 | GDC-0449 (Vismodegib) | Smo |
| Vismodegib, HhAntag691 | ||
| GDC-0449 (Vismodegib) is a potent and specific hedgehog pathway inhibitor with IC50 values of 1.4 and 3.0μM for inhibition of ABCG2 and Pgp respectively. | ||
| M1721 | AZD4547 | FGFR |
| Fexagratinib; ABSK091 | ||
| AZD4547 is a potent, selective and orally active pan-FGFR inhibitor with IC50s of 0.2. 2.5, 1.8 and 165 nM for FGFR1, 2, 3 and 4, respectively. | ||
| M1734 | BAY-60-7550 | PDE |
| BAY 607550 | ||
| BAY-60-7550 is a potent PDE2 inhibitor with IC50 values of 2.0 nM (bovine) and 4.7 nM (human). | ||
| M1736 | CH5132799 | PI3K |
| CH5132799 is a novel and potent class I PI3K inhibitor with IC50 value of 0.014 μM. | ||
| M1742 | Tubacin | HDAC |
| Tubulin Acetylation Inducer | ||
| Tubacin (Tubulin Acetylation Inducer) is a highly potent and selective, reversible cell-permeable inhibitor of HDAC6 with IC50 of 0.004µM. | ||
| M1761 | Vemurafenib (PLX4032) | Raf |
| RG7204; RO5185426 | ||
| Vemurafenib (PLX4032) is a first-in-class, potent, selective inhibitor of B-Raf that inhibits RAFV600E and C-RAF-1 activity with IC50s of 31 nM and 48 nM, respectively.In addition, Vemurafenib induces autophagy. | ||
| M1765 | Crizotinib (PF-02341066) | c-Met |
| Crizotinib | ||
| Crizotinib (PF-02341066) is a potent, orally bioavailable, ATP-competitive small-molecule inhibitor of c-Met kinase and ALK (anaplastic lymphoma kinase) with IC50 values to be 4 and 25 nM for C-Met and ALK resepectively. | ||
| M1772 | PKI-587 | PI3K |
| PF-05212384 | ||
| PKI-587 (PF-05212384) is a highly potent dual PI3K/mTOR kinase inhibitor with the IC50 value of 0.4nM. | ||
| M1773 | PI-103 | PI3K |
| PI103 | ||
| PI-103 is a potent, ATP-competitive PI3K,cell-permeable,inhibitor.The IC50 values are 2, 8, 20, 26, 48, 83, 88, 150 nM for DNA-PK, p110α, mTORC1, PI3-KC2β, p110δ, mTORC2, p110β, and p110γrespectively. | ||
| M1786 | Ispinesib | Kinesin |
| SB-715992, CK0238273 | ||
| Ispinesib (SB 715992) is the first potent, highly specific small-molecule inhibitor of kinesin spindle protein (KSP) with an IC50 of 4.1 nM. | ||
| M1794 | SB431542 | ALK |
| SB-431542 | ||
| SB-431542 is a potent and selective inhibitor of the transforming growth factor-β (TGF-β) type I receptor activin receptor-like kinase ALK5 (IC50 = 94 nM). | ||
| M1796 | XAV939 | Wnt/beta-catenin |
| NVP-XAV939; XAV-939 | ||
| XAV939 is a potent, cell-permeable small molecule inhibitor of the Wnt/β-catenin pathway to TNKS1 and TNKS2 with IC50 values of 11 and 4 nM respectively. | ||
| M1804 | NVP-BSK805 dihydrochloride | JAK |
| NVP-BSK805, BSK805 2HCl | ||
| NVP-BSK805 dihydrochloride is a potent and selective quinoxaline JAK2 inhibitor with IC50 values of 0.48, 0.56 and 0.58 nM for JAK2 JH1, FL JAK V617F and FL JAK2 wt respectively. | ||
| M1807 | SCH727965 (dinaciclib) | CDK |
| Dinaciclib | ||
| SCH727965 (Dinaciclib) is a potent and selective CDK inhibitor with IC50 values of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively. | ||
| M1809 | NU7441 | PI3K |
| KU 57788 | ||
| NU7441 (KU 57788) is a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor with IC50 values of 14, 1700, 5000, >100000 and >100000 nM for DNA-PK, mTOR, PI 3-K, ATM and ATR respectively. | ||
| M1813 | PCI-24781 | HDAC |
| Abexinostat; CRA-024781 | ||
| PCI-24781 is a novel and potent histone deacetylase (HDAC) inhibitor with IC50 value of 0.43 to 2.7 μM. *The compound is unstable in solutions, freshly prepared is recommended | ||
| M1817 | Y-27632 dihydrochloride | ROCK |
| Y27632; Y-27632 2HCl | ||
| Y-27632 is a potent, selective inhibitor of Rho-associated protein kinases (ROCK) with IC50 values of 140-220 nM for ROCK1 and ROCK2. In addition, Y-27632 inhibited LPA-induced entosis. | ||
| M1819 | A66 | PI3K |
| A66 is a potent and specific inhibitor of PI3K p110α with IC50 values of 32, 30 and 43 nM for p110α, p110α/E545K and p110α/H1047R. | ||
| M1824 | SRT1720 Hydrochloride | Sirtuin |
| SRT-1720 Hydrochloride | ||
| SRT1720 Hydrochloride is a selective small molecule activator of SIRT1 that is 1,000-fold more potent than resveratrol (EC1.5 = 0.16 versus 46.2 µM, respectively). SRT1720 increased the activity of SIRT1 and AMPKα phosphorylation at Ser485 via the cAMP-protein kinase A (PKA) pathway. | ||
| M1825 | PCI-32765 | BTK |
| Ibrutinib; CRA-032765 | ||
| PCI-32765 (Ibrutinib) is a potent, selective and orally bioavailable irreversible inhibitor of BTK with IC50 value of 0.46 nM. | ||
| M1840 | BGJ398 (Infigratinib) | FGFR |
| NVP-BGJ398; Infigratinib | ||
| BGJ398 (Infigratinib) is a potent and selective FGFR kinase inhibitor with IC50 values of 0.9 nM, 1.4 nM, 1 nM and 60 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
